Sean D. Candrilli
0000-0002-2062-1192
Publication & Citation Trends
Most Cited Works
Publications
150 total
Prevalence of health conditions associated with higher risk for severe respiratory syncytial virus, influenza, or COVID-19
Cited by 1
Semantic Scholar
Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer OA
Cited by 0
Semantic Scholar
Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis.
Cited by 0
Semantic Scholar
Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer OA
Cited by 4
Semantic Scholar
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study
Cited by 42
Semantic Scholar
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
Cited by 7
Semantic Scholar
Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
Cited by 7
Semantic Scholar
HPR184 Social Determinants of Health (SDoH) and Other Predictors in Treatment Initiation with CDK4/6 Inhibitors in Medicare Patients with HR+/HER2– Metastatic Breast Cancer (MBC)
Cited by 0
Semantic Scholar
Research Topics
Emergency and Acute Care Studies
(8)
Chronic Lymphocytic Leukemia Research
(7)
Chronic Myeloid Leukemia Treatments
(7)
Sarcoma Diagnosis and Treatment
(6)
Healthcare Policy and Management
(6)
Frequent Co-Authors
Affiliations
Research Triangle Park Foundation
Nationwide Children's Hospital
Bayer (United States)
RTI International
Wayne State University